2022年12月29日

我們可以從本頁上的鏈接賺取傭金。與輝瑞公司合作開發新冠疫苗的德國生物技術公司BioNTech將把其首個模塊化mRNA疫苗工廠運往盧旺達。這家名為BioNTainer的工廠建在德國，由一個模塊組成，可以批量生產mRNA疫苗。這使得BioNTech繞過了在當地技術有限的情況下建立工廠的質量挑戰，並分享了與mRNA疫苗生產相關的知識。隻有填充和整理工作將由加納和南非的當地合作夥伴完成。BioNTech廣告公司上周宣布，組成該模塊的六個集裝箱已經過檢查，準備運往基加利，預計將在2023年第一季度到達。疫苗生產應於2024年初開始，大約在集裝箱交付後一年。交鑰匙製造工廠BioNTech在2022年2月宣布了“交鑰匙信使rna製造設施”的計劃，計劃在2022年中期將第一批集裝箱運往盧旺達。進展被推遲了，但一旦建成並運行，該設施預計將每年生產5000萬劑covid疫苗。這家德國公司計劃將另一家類似的工廠運往塞內加爾，可能還有南非，那裏正在計劃開發當地的mRNA疫苗中心。 Advertisement At the same time, BioNTech has started construction of a traditional manufacturing facility in Kigali. That work began in June 2022. First of a series The vaccines manufactured in the BioNTainers will be sold in the African region on a not-for-profit basis. BioNTech will initially staff the prefabricated facility in Rwanda, though it plans to eventually train and hire local workers. The supply of BioNTainers is small against the need in the region for covid vaccines . But more modules could be added, expanding the capacity, and the facility potentially can be used for future production of other locally relevant vaccines. BioNTech is working on mRNA vaccine candidates for malaria and tuberculosis , for which it has already begun human trials . ???? Need to Know: Davos 2023 A daily dispatch from the annual meeting of the World Economic Forum.